= Emerging. More than 5 years before clinical availability. (26.55%)
= Expected to be clinically available in 1 to 4 years. (39.66%)
= Clinically available now. (33.79%)
MSACL 2020 US : Bensussan

MSACL 2020 US Abstract

Topic: Imaging

Podium Presentation in Room 4 on Wednesday at 14:20 (Chair: Reid Groseclose / Aalim Weljie)

Integrating Desorption Electrospray Ionization Mass Spectrometry Imaging and Fluorescence In-situ Hybridization for the Detection of Circulating Tumor Cells

Alena Bensussan (Presenter)
University of Texas at Austin

Authors: Alena Bensussan (1), John Lin (1), Tanweer Zaidi (2), Ruth Katz (2), Livia Eberlin (1)
(1) University of Texas at Austin, Austin, TX (2) MD Anderson Cancer Center, Houston, TX

Abstract

This abstract is currently under embargo.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no